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Abstract
A competitive exclusion product is described which includes a substantially pure culture of the bacterium
species Serpulina pilosicoli, or a genetic equivalent thereof. When administered to an animal, the S. pilosicoli
colonizes the cecal wall to prevent the colonization of other harmful bacteria, thereby preventing disease.
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(57) ABSTRACT 
A competitive exclusion product is described Which includes 
a substantially pure culture of the bacterium species Ser 
pulina pilosicoli, or a genetic equivalent thereof. When 
administered to an animal, the S. pilosicoli coloniZes the 
cecal Wall to prevent the colonization of other harmful 
bacteria, thereby preventing disease. 
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SERPULINA PILOSICOLI COMPETITIVE 
EXCLUSION PRODUCT 
CROSS-REFERENCE TO A RELATED 
APPLICATION 
This application is a continuation-in-part of commonly 
assigned provisional application Ser. No. 60/053,423, ?led 
Jul. 22, 1997, noW abandoned, and application Ser. No. 
09/119,861, ?led Jul. 21, 1998 noW abandoned, the disclo 
sures of Which are hereby incorporated by reference. 
BACKGROUND OF THE INVENTION 
Microorganism populations in animal digestive systems 
are enormously complex biological ecosystems. Microor 
ganisms normally inhabit the gastrointestinal tracts of 
human beings and other animals Without invading the deeper 
tissues to cause disease. These microbes are consistently 
present in varying proportions. Their pattern of groWth, 
conspicuously bacterial, is associated With the Well-being of 
the animal and is necessary to its health. 
Literally hundreds of species have been identi?ed from 
animal intestinal tracts, and their populations can exceed 
100 billion/g contents. 
Typical residents of the gastrointestinal tract include 
coliforms, enterococci, Clostridium species, Proteus species, 
yeasts, Penicillium species, enteroviruses, Pseudomonas 
aeruginosa, aerobic and anaerobic streptococci, 
staphylococci, enterococci, Alcaligenes faecalis, Bacteroi 
des species, and Lactobacillus species. 
Microbial groWth in the gastrointestinal tract is much 
more plentiful in the large intestine than the small intestine. 
The large intestine extends from the ileum to the anus and 
includes the cecum With vermiform appendix, colon, and 
rectum. The cecum is a blind pouch or cul-de-sac Which 
forms the ?rst portion of the large intestine. It is located 
beloW the entrance of the ileum at the ileocecal valve. 
The age of the animal has a profound effect on intestinal 
physiology and microbial populations. Animals are born 
With a sterile intestinal tract and become coloniZed by those 
microbes in feed, or from their environment. Adult animals 
have a generally stable micro?ora that is usually disturbed 
only by drugs, disease, stress, or marked dietary changes. 
The interaction betWeen the animal, its environment, diet, 
and its residential microbial gut community is poorly under 
stood. Inferences from the microbial balance have been 
made for the presence or absence of the disease state, and for 
reduced animal performance. 
As an example, failure of chickens to reach expected 
levels of egg production is a problem frequently encountered 
in commercial egg-producing operations. Reduced egg pro 
duction can be caused by a variety of viral, bacterial, toxic, 
and nutritional etiologies. 
Commercial chickens in the United States and Europe 
have been reported to be infected With pathogenic intestinal 
spirochetes. In 1955, spirochetes Were observed in cecal 
nodules of chickens, and these lesions Were reproduced in 
chickens and turkeys by oral administration of infected cecal 
material. Mathey, W. J ., et al. (1955), Spirochetes and cecal 
nodules in poultry. J. Am. Vet. Med. Assoc. 126:475—477. In 
1986, it Was reported that the isolation of a Weakly 
hemolytic spirochete from the cecal mucosa of hens With 
diarrhea, chickens and sWine from the same farm had a 
history of intermittent diarrhea. Davelaar, F. G., et al. (1986), 
Infectious typhlitis in chickens caused by spirochetes. Avian 
Pathol. 15 :247—258. A subsequent ?uorescent antibody 
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microscopic study identi?ed intestinal spirochetes in 27.6% 
of ?ocks With intestinal disorders and in 4.4% of ?ocks 
lacking signs of enteritis. DWars, R. M., et al. (1989), 
Incidence of spirochetal infections in cases of intestinal 
disorders in chickens. Avian Pathol. 18:591—595. Retarded 
groWth rates and delayed onset of egg production Were 
associated With spirochete infection of pullets in Great 
Britain. Grif?ths, I. B., et al. (1987), Retarded groWth rate 
and delayed onset of egg production associated With spiro 
chete infection in pullets. Vet. Rec. 121:35—37. The latter 
chickens Were reared on deep litter and had indirect contact 
With sWine. Further, pasty vents and dirty eggshells in Ohio 
laying hens shortly after molting Were associated With cecal 
spirochetes. SWayne, D. E., et al. (1992), Association of 
cecal spirochetes With pasty vents and dirty eggshells in 
layers. Avian Dis. 36:776—781. 
While the above reports indicated an association betWeen 
cecal spirochetes and infection in chickens, the oral admin 
istration of human spirochetes to broiler chicks did not cause 
clinical signs of disease or gross lesions. DWars, R. M., et al. 
(1992), Infection of broiler chicks (Gallus domesticus) With 
human intestinal spirochaetes. Avian Pathol. 21:559—568. 
HoWever, inoculating avian intestinal spirochetes into the 
crop of hens resulted in Wet droppings and invasion of 
spirochetes into and beneath cecal epithelium. DWars, R. M., 
et al. (1990), Observations on avian intestinal spirochaeto 
sis. Vet. O. 12:51—55. 
In 1993, it Was determined that intestinal cecal spiro 
chetes Were a cause of reduced egg production during the 
early part of the ?rst laying cycle. Trampel, D. W., et al. 
(1994), Cecal Spirochetosis in Commercial Laying Hens. 
Avian Dis. 38:895—898. In this study, affected chickens 
necropsied Were found to have an orderly, dense, uniform 
layer of spirochetes covering the entire mucosal surface of 
the ceca. Id. 
Current treatments for intestinal pathogens have included 
treatment With therapeutic drugs, such as antimicrobials, to 
eradicate or decrease the number of pathogens. HoWever, if 
the animal is a domesticated livestock animal used for 
human food consumption, adulteration of the carcass With 
drugs is not desirable. 
Other treatments for intestinal pathogens in poultry and 
other livestock have included the administration of competi 
tive exclusion products. Direct feed microbials have been 
successfully used to replenish the gut bacterial population 
With natural bene?cial bacteria. One such product, sold 
under the trade name Preempt®, contains 29 different spe 
cies of bacteria. It is desirable to narroW the strains of the 
direct feed microbials to those minimum number of strains 
Which are efficacious in order to decrease cost and to 
maximiZe bene?t to the animal. In fact, one of the greatest 
dif?culties With these direct feed treatments has been to ?nd 
Which strains from the Wide consortium of bacteria, are truly 
effective in producing the desired result in animals, and 
especially livestock. 
It has noW been discovered that a single, de?ned bacte 
rium is effective in reducing or eliminating diseases caused 
by undesirable microbes Which coloniZe the ceca of animals. 
The bacteria corrects the pathology of the animal’s system 
in such a manner that the host animal is quickly returned to 
an economically producing animal. 
Accordingly, it is a primary objective of the present 
invention to provide a competitive exclusion product to 
provide a method of enhancing the overall Well-being of 
poultry by use of a single, de?ned bacterium. 
It is a further objective of the present invention to provide 
a competitive exclusion product Which, When fed, corrects 
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the pathology of the animal system in such a manner that the 
host animal is quickly returned to an economically produc 
ing animal. 
It is another objective of the present invention to provide 
a competitive exclusion product in the form of a direct-fed 
microbial composition Which can be fed in conjunction With 
daily free choice feed rations. 
It is yet another objective of the present invention to 
provide a competitive exclusion product Which can be fed to 
poultry in order to increase overall health, Well being, and in 
general, increase the economics of the animal to its pro 
ducer. 
It is still a further objective of the present invention to 
provide a competitive exclusion product Which contains 
only one, de?ned bacterium, and therefore does not contain 
extraneous, costly and unnecessary strains of bacteria. 
It is another objective of the present invention to provide 
a competitive exclusion product Which is safe and economi 
cal to administer to the animal. 
The method and means of accomplishing each of the 
above objectives as Well as others Will become apparent 
from the detailed description of the invention Which folloWs 
hereafter. 
SUMMARY OF THE INVENTION 
The invention describes a method and means for eradi 
cating or decreasing the number of disease-causing microbes 
in the intestinal tract of poultry. The invention has been 
found to be especially effective in treating cecal spiroche 
tosis in poultry. The treatment involves the administration of 
the single bacterium Serpulina pilosicoli, or the genetic 
equivalents thereof. The preferred strain of Serpulina pilosi 
coli is laboratory strain 42167 (S. pilosicoli 42167). The 
bacteria are administered orally in conjunction With feed or 
Water rations. FolloWing administration, the bacteria colo 
niZe the ceca to the extent that other harmful bacteria, such 
as Salmonella and Camphylobacter, are prevented from 
attaching to the cecal Wall. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
As earlier described, the invention herein relates to 
administering to poultry for a period of time a small, but 
disease-preventing effective amount of a competitive exclu 
sion product. The product includes the spiral-shaped bacte 
rium Serpulina pilosicoli, or the genetic equivalent thereof. 
The preferred bacteria strain is S. pilosicoli 42167. 
The term “genetic equivalent” as used herein is to be 
understood to mean not only the precise species Serpulina 
pilosicoli, but mutants thereof, or genetically altered bacteria 
Which nevertheless have a common identifying characteris 
tic of successful performance in the present invention. 
This invention has been found to be particularly effective 
in poultry, Which is intended to include domestic poultry, 
such as chickens, turkeys, and ducks. Chickens are inclusive 
of broiler (meat-type) chickens and leghorn (egg-type) 
chickens. 
From time to time, reference is made to a biologically 
pure or substantially pure culture of the above referred to 
bacteria species. This is intended to refer to a culture Which 
contains no other bacterial species in quantities suf?cient 
that they interfere With the effectiveness of the S. pilosicoli. 
It is important that cultures be substantially free of interfer 
ing bacteria, since other bacteria either have no effect or may 
have a detrimental effect on achieving the objectives of the 
invention. 
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Further, the Serpulina pilosicoli bacteria of this invention 
are substantially live, non-pathogenic organisms. “Substan 
tially live, substantially non-pathogenic organisms” is herein 
de?ned as organisms Which contain an insuf?cient amount 
of dead or disease-producing organisms to interfere With the 
effectiveness of the bacteria. S. pilosicoli 42167 is an 
example of a strain of Serpulina pilosicoli that is substan 
tially non-pathogenic. 
Serpulina pilosicoli is easily diagnosed microscopically, 
but has been identi?ed only during the last feW years, and 
received a scienti?c name only about tWo years ago. The 
?nding of this organism in chickens is rare. There is no 
evidence suggesting that Serpulina pilosicoli is part of the 
normal intestinal ?ora of chickens. 
Generally speaking, the bacteria described herein should 
be administered in a preventative manner before disease, but 
certainly as soon as disease is noted. A preferred method is 
to administer a single dose of the bacteria Within the ?rst 
Week of life of the animal, and most preferably during the 
?rst day of life. The bacteria can be given to the animal 
through its Water or feed. The bacteria may also be admin 
istered With other non-toxic carriers in the form of an 
injection, oral innoculation, or intravenous administration. 
Such non-toxic carriers are Well knoWn in the art and include 
Water, saline, and non-toxic vegetable oil. 
FolloWing administration, the bacteria coloniZe the cecum 
of the animal. The coloniZation of the bacteria is so exten 
sive on the Wall of the cecum that other undesirable bacteria, 
such as Salmonella and spirochetes, cannot attach to the 
cecal Wall themselves. Thus, the undesirable bacteria cannot 
invade the animal’s body and cause disease. 
The level of the organism count should be Within the 
range of 101 organisms to about 109 organisms/gram of diet, 
preferably from about 102 to about 104 organisms/gram of 
diet. The diet can then be administered to the animals ad 
libium or on a scheduled basis. 
The manner of administering the bacteria may be by 
conventional mixing With feed or Water. The feed or Water 
is thereafter fed in a free choice manner. 
The present invention offers the advantages of providing 
a singular source of bacteria, a spirochete, Which is more 
effective in coating the inner surface of the cecal Wall than 
other knoWn competitive exclusion products. This dense, 
uniform coating of S. pilosicoli prevents other disease 
causing bacteria, such as other strains of spirochetes, 
Salmonella, and Campylobacter, from attaching to the cecal 
Wall. Since the competitive exclusion product of the present 
invention includes only the single bacterium S. pilosicoli, it 
is easier and less expensive to mass produce. Further, it is 
easier to monitor in treated birds. 
The folloWing examples are offered to illustrate but not 
limit the invention. Thus, they are presented With the under 
standing that various formulation modi?cations as Well as 
method of delivery modi?cations may be made and still be 
Within the spirit of the invention. 
EXAMPLE 1 
Pathogenicity of a Chicken Strain of 
Serpulinapilosicoli 
Materials and Methods 
20 pathogen-free, White leghorn chicks Were used in the 
experiment. Ten Were used as controls and ten Were admin 
istered S. pilosicoli 42167 in their feed. The tWo groups of 
chicks Were kept in separate brooder units. 
The use of speci?c pathogen free (SPF) chickens, as in 
this experiment, is standard procedure throughout the United 
US 6,315,993 B1 
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States. Research involving microorganisms and chickens 
should always be done in SPF chickens so that one can be 
reasonably sure that observations can be attributed to the 
experimental microorganism administered. Other chickens 
(non-SPF) may already possess microorganisms that Would 
invalidate the experimental results. 
The control and S. pilosicoli groups Were inoculated 2 
days posthatch. The control group Was inoculated With BHIS 
medium and the S. pilosicoli group Was given spirochetes in 
a concentration of 108 spirochetes/ml. The inoculations Were 
in 0.5 ml increments via crop gavage. Three inoculations 
Were administered at 4 hour intervals. 
Parameters Measured 
The chicks Were observed for the folloWing parameters in 
the folloWing frequencies: 
Observation Frequency 
Clinical signs daily 
Body Weights Weekly 
Cloacal cultures Weekly 
Excreta dry matter 3 Weeks PI 
Excreta fat content 3 Weeks PI 
Pathology 3 Weeks PI 
ELISA titers 3 Weeks PI 
Results and Discussion 
TABLE 1 
Cloacal Isolation of Sergulina gilosicoli 
Days Postinoculation 
Group —1 7 14 21 
Control 0 0 0 0 
S. pilosicoli 0 5 4 8 
TABLE 2 
Cecal Colonization 21 days PI 
Extent Controls S. pilosicoli 
Slight 0 3 
Moderate 0 0 
Heavy 0 7 
As shoWn above, Tables 1 and 2 demonstrate that ceca of 
chickens become coloniZed by S. pilosicoli upon oral expo 
sure. 
TABLE 3 
ELISA Serology 
Group Titer 
Control 0.052 
S. pilosicoli 0.144" 
"P 2 0.005 
Neither group shoWed any clinical signs of diarrhea or 
depression. 
Table 3 demonstrates that chickens develop an immune 
response to S. pilosicoli. 
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TABLE 4 
Mean Body Weights 
Davs Postinoculation 
Group —1 7 14 21 
Control 34.7 57.6 119.2 169.9 
S. pilosicoli 34.4 51.1 132.5 194.3 
Table 4 demonstrates that chickens inoculated With S. 
pilosicoli gain Weight faster than chickens that are not 
inoculated. 
TABLE 5 
Dry Matter Content of Excreta 
% of Weight 
Days Postinoculation 
Group 7 14 21 
Control 51.1 48.9 45.8 
S. pilosicoli 58.4 50.5 41.4 
Table 5 demonstrates that chickens inoculated With S. 
pilosicoli do not develop diarrhea. Dry-matter content of 
feces Was not signi?cantly different from the control. 
TABLE 6 
Fat Content of Excreta 
% of Dry Matter 
Days Postinoculation 
Group 7 14 21 
Control 1.20 1.35 1.10 
S. pilosicoli 1.72 1.16 1.11 
Table 6 demonstrates that absorption of fat is not different 
betWeen the S. pilosicoli-inoculated chickens and the control 
group. 
Conclusions 
The study demonstrates that Serpulina pilosicoli readily 
coloniZes the ceca of 2-day-old chicks. The chicks infected 
With a chicken strain of S. pilosicoli Were asymptomatic. The 
end-on-attachment of the bacteria is via indentation of apical 
enterocyte cell membranes. Antibodies can be detected by 
ELISA by 21 days folloWing oral exposure. 
Not only Was the Serpulina pilosicoli bacteria 
nonpathogenic, but it Was also bene?cial. As shoWn above, 
the inoculated chickens gained Weight faster than the control 
birds. 
As shoWn above, the competitive exclusion product of the 
present invention antimicrobial composition of the present 
invention is effective in coloniZing the cecal Wall of poultry. 
It also prevents other harmful bacteria from attaching to the 
animal’s cecal Wall, thereby reducing diarrhea and other 
diseases in the animal and further increasing the animal’s 
productivity. The use of a competitive exclusion product 
containing only one bacterium offers the advantages of 
being less expensive to produce in large quantities and, in 
addition, makes it easier for the caregiver to monitor the 
treated birds. It is therefore submitted that the present 
invention accomplishes at least all of its stated objectives. 
Deposits 
A deposit of S. pilosicoli 42167 is and has been main 
tained by the inventor since prior to the ?ling date of this 
application. Access to this deposit Will be available during 
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the pendency of the application to the Commissioner of 
Patents and Trademarks and persons determined by the 
Commissioner to be entitled thereto upon request. Upon 
allowance of any claims in the application, the Applicant 
Will make available to the public Without restriction a 
deposit With the American Type Culture Collection (ATCC), 
10801 University Boulevard, Manassas, Va. 20110—2209. 
The organisms deposited With the ATCC Will be taken from 
the same deposit maintained by the inventor and described 
above. Additionally, Applicant Will meet all the require 
ments of 37 C.F.R. §1.801—1.809, including providing an 
indication of the viability of the sample When the deposit is 
made. this deposit of S. pilosicoli 42167 Will be maintained 
in the ATCC Depository, Which is a public depository, for a 
period of 30 years, or 5 years after the most recent request, 
or for the enforceable life of the patent, Whichever is longer, 
and Will be replaced if it ever becomes nonviable during that 
period. Applicant Will impose no restrictions on the avail 
ability of the deposited material from the ATCC; hoWever, 
Applicant has no authority to Waive any restrictions imposed 
by laW on the transfer of biological material or its transpor 
tation in commerce. Applicant does not Waive any infringe 
ment of its rights granted under this patent. 
Having described the invention With reference to particu 
lar compositions, theories of effectiveness, and the like, it 
Will be apparent to those of skill in the art that it is not 
intended that the invention be limited by such illustrative 
embodiments or mechanisms, and that modi?cations can be 
made Without departing from the scope or spirit of the 
invention, as de?ned by the appended claims. It is intended 
that all such obvious modi?cations and variations be 
included Within the scope of the present invention as de?ned 
in the appended claims. The claims are meant to cover the 
claimed components and steps in any sequence Which is 
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effective to meet the objectives there intended, unless the 
conteXt speci?cally indicates to the contrary. 
I claim: 
1. A method of manufacturing a composition useful for 
coloniZing the intestinal tract of an animnal that is a member 
of the poultry group comprising: 
combining an amount of a live, biologically pure culture 
of Serpulina pilosicoli 42167 effective for coloniZing 
the intestinal tract of poultry With a non-toXic carrier. 
2. A composition for poultry useful for coloniZing the 
intestinal tract of poultry comprising: 
an amount of a live, biologically pure culture of Serpulina 
pilosicoli 42167 effective for coloniZing the intestinal 
tract of poultry; and 
poultry feed or Water. 
3. A composition for administration to an animal that is a 
member of the poultry group to prevent disease-causing 
microbes from coloniZing the intestinal tract of the animal 
comprising: 
an amount of a live, biologically pure culture of Serpulina 
pilosicoli 42167 effective for coloniZing the intestinal 
tract of poultry; and 
a non-toxic carrier. 
4. The composition according to claim 3 further including 
feed or Water of the animal, Whereby said culture is admixed 
With the feed or Water. 
5. The composition according to claim 3 Wherein the 
culture is present in a concentration of from about 101 to 109 
organisms per gram of animal diet. 
6. The composition according to claim 3 Wherein the 
animal is a chicken. 
